Adagio(IVVD) ZACKS·2025-03-20 14:25Company Performance - Invivyd, Inc. reported a quarterly loss of $0.15 per share, better than the Zacks Consensus Estimate of a loss of $0.25, and improved from a loss of $0.67 per share a year ago, representing an earnings surprise of 40% [1] - The company posted revenues of $13.82 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.75%, compared to zero revenues a year ago [2] - The stock has increased approximately 62.5% since the beginning of the year, contrasting with the S&P 500's decline of 3.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $33.35 million, and for the current fiscal year, it is $0.11 on revenues of $172.15 million [7] - The estimate revisions trend for Invivyd, Inc. is favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Invivyd belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]